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he NIEHS is pleased to announce that Christopher A. Bradfield, 
a professor of oncology at the University of Wisconsin at Madison,
and Michael B. Kastan, chairman of the Department of
Hematology/Oncology at St. Jude Children’s Research Hospital, have each
received an award under the Method to Extend Research in Time (MERIT)
Award Program. MERIT awards are offered to investigators who have
demonstrated superior skill and outstanding productivity during the course
of their previous research endeavors. MERIT awards relieve investigators from
writing frequent renewal applications by providing the opportunity to gain up
to 10 years of support in two segments.
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Bradfield is interested in understanding the
significance and role of the family of
transcriptional regulators known as PAS proteins,
which control a number of
processes including xenobiotic
metabolism, circadian rhythms,
angiogenesis, and neurogenesis. For
the past 10 years he has
concentrated on the upstream
events in the Ah receptor (AHR)
signal transduction pathway and
showing the importance of the PAS
domain in binding and dimerization with its
partner protein ARNT (AHR nuclear
translocator). He has developed genetic systems in
yeast and mice that allow first the identification of
genes required in signaling pathways and then an
understanding of the physiological function of the
proteins. He is a recognized leader in the field of
the mechanism of dioxin action, and his research
is widely held to engage in state-of-the-art
approaches with innovative applications. Findings
from these approaches will not only be important
for an understanding of the function and control
of the AHR, but also for understanding the role of
PAS proteins as environmental sensors.
Kastan is a recognized leader in the field of
signal transduction pathways, conducting
important basic research in elucidating the
molecular steps involved in
cellular responses to DNA
damage. He observed that wild-
type p53 protein was induced
following DNA damage in cells,
and that p53, a commonly
mutated gene in cancer tumors,
exerts its growth-inhibitory effects
following certain types of DNA
damage. Exposure to environmental
carcinogens—the majority of which damage
DNA—appears to contribute to the development
of a high percentage of human tumors. Therefore,
slinking this commonly mutated cancer gene to
the control of cell cycle arrest and apoptosis
following DNA damage has provided invaluable
insights into mechanisms of tumor development
in humans. In addition, p53 is involved in the
stress-signaling pathway and is a central mediator
activated in response to oxidant injury. His
continued research into p53 signaling should
provide significant new information that has
implications for both environmental
carcinogenesis and tumor therapy.
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